Sangamo Therapeutics

SGMOQ · OTC · United States

Share price · SGMOQ

$0.16+0.03 (+23.08%) 3M

no price since 18 Aug 2026

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when SGMOQ's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 3 Aug 2026+28.6%

    Nothing announced by SGMOQ that day or the session before.

  2. 24 Jun 2026-28.6%
  3. 23 Jun 2026-58.8%
  4. 5 May 2026-38.9%

    Nothing announced by SGMOQ that day or the session before.

  5. 4 May 2026+28.6%

    Nothing announced by SGMOQ that day or the session before.

  6. 1 May 2026+16.7%

    Nothing announced by SGMOQ that day or the session before.

  7. 29 Apr 2026-35.0%
  8. 24 Apr 2026-26.9%

    Nothing announced by SGMOQ that day or the session before.

  9. 31 Mar 2026-19.4%
  10. 24 Feb 2026+20.5%

    Nothing announced by SGMOQ that day or the session before.

Share of unusual movement by asset

For each asset, the share of SGMOQ's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—36%
Sessions with no dated event—64%

No dated announcements about its assets since 2 Jul 2024.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1/2
HLA-A*02 (CAR-Treg)Cell therapy
Organ Transplant Rejection
Kidney Transplant Rejection Prophylaxis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (14)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$1.4M$27M$28M$31M-$19M operating cash flowreport ↗
View 13 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3$0.6M$28M$31M+ $0 short-term inv.$35M-$29M operating cash flowreport ↗
2025-Q2$18M$27M$40M+ $0 short-term inv.$20M-$18M operating cash flowreport ↗
2025-Q1$6.4M$26M$27M+ $0 short-term inv.$31M-$26M operating cash flowreport ↗
2024-Q3$49M$28M$41M+ $0 short-term inv.—$12M operating cash flowreport ↗
2024-Q2$0.4M$24M$28M+ $0 short-term inv.$36M-$27M operating cash flowreport ↗
2024-Q1$0.5M$36M$55M+ $0 short-term inv.$49M-$49M operating cash flowreport ↗
2023-Q3$9.4M$57M$58M+ $76M short-term inv.$104M-$47M operating cash flowreport ↗
2023-Q2$6.8M$63M$68M+ $76M short-term inv.$115M-$61M operating cash flowreport ↗
2023-Q1$158M$63M$80M+ $127M short-term inv.—-$66M operating cash flowreport ↗
2022-Q3$26M$65M$96M+ $219M short-term inv.$53M-$54M operating cash flowreport ↗
2022-Q2$29M$60M$119M+ $198M short-term inv.$43M-$54M operating cash flowreport ↗
2022-Q1$28M$59M$122M+ $198M short-term inv.$44M-$59M operating cash flowreport ↗
2021-Q3$29M$63M$178M+ $246M short-term inv.$48M-$59M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$40M$113M$21M+ $0 short-term inv.$31M-$97M operating cash flowreport ↗

Sangamo Therapeutics reported full-year 2025 revenue of $39.55M, down 31.6% YoY, with R&D spend of $112.67M, up 1.0% YoY. The company held cash and equivalents of $20.95M, reported a net loss of $122.93M, and a quarterly net burn of $122.93M.

During the year, Sangamo initiated a rolling BLA submission for isaralgagene civaparvovec in Fabry disease, received FDA Fast Track designation for ST-503 in small fiber neuropathy, advanced CTA-enabling activities for ST-506 in prion disease, and regained development and commercialization rights to the hemophilia A candidate giroctocogene fitelparvovec from Pfizer. The company is pursuing collaboration agreements to fund operations and disclosed substantial doubt about its ability to continue as a going concern.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$58M$112M$43M+ $0 short-term inv.$24M-$67M operating cash flowreport ↗
2023-FY$176M$234M$47M+ $36M short-term inv.$64M-$225M operating cash flowreport ↗
2022-FY$111M$250M$102M+ $177M short-term inv.$48M-$224M operating cash flowreport ↗
2021-FY$111M$231M$180M+ $198M short-term inv.$45M-$233M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 2 sales ($107K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-05-25Macrae Sandy · director, PRESIDENT, CEO AND DIRECTORTax withholding12,613$0.17$2KForm 4
2026-05-25Willoughby Scott B. · SVP, CHIEF LEGAL OFFICER, SECYTax withholding4,036$0.17$703Form 4
2026-05-25Dubois-Stringfellow Nathalie · SVP-CHIEF DEVELOPMENT OFFICERTax withholding4,036$0.17$703Form 4
2026-05-25Jain Nikunj · Principal Accounting OfficerTax withholding1,919$0.17$334Form 4
2026-05-25Davis Gregory D · Head of Research & TechnologyTax withholding1,630$0.17$284Form 4
2026-04-22Davis Gregory D · Head of Research & TechnologyOpen-market sale69,827$0.25$18KForm 4
2026-04-21Dubois-Stringfellow Nathalie · SVP-CHIEF DEVELOPMENT OFFICEROpen-market sale345,942$0.26$89KForm 4
2026-04-01Willoughby Scott B. · SVP, CHIEF LEGAL OFFICER, SECYAward / grant (derivative)800,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 112 reporting institutions held 105.4M shares ($26.0M, 25.4% of shares outstanding).

#InstitutionSharesValue
1ARMISTICE CAPITAL, LLC40,400,067$10.0M
2VANGUARD CAPITAL MANAGEMENT LLC12,704,408$3.1M
3TWO SIGMA INVESTMENTS, LP6,270,441$1.5M
4Balyasny Asset Management L.P.5,288,097$1.3M
5GEODE CAPITAL MANAGEMENT, LLC4,570,862$1.1M
6BlackRock, Inc.4,547,848$1.1M
7RENAISSANCE TECHNOLOGIES LLC3,836,665$947K
8UBS Group AG2,570,992$635K
9CHARLES SCHWAB INVESTMENT MANAGEMENT INC2,352,360$581K
10VANGUARD FIDUCIARY TRUST CO2,310,297$571K
11JACOBS LEVY EQUITY MANAGEMENT, INC2,050,384$506K
12BANK OF AMERICA CORP /DE/1,838,390$452K
13STATE STREET CORP1,694,783$418K
14SUSQUEHANNA INTERNATIONAL GROUP, LLP1,687,463$417K
15LUMINUS MANAGEMENT LLC1,681,089$415K